Related Experiment Videos
[Atorvastatin in secondary prevention]
Zeki Ongen1, Yeşim Yilmaz, Bilgehan Karadağ
1Department of Cardiology, Cerrahpaşa Medical Faculty of Istanbul University, Istanbul, Turkey. z_ongen@yahoo.com.tr
Summary
Atorvastatin effectively reduces clinical events in secondary prevention for coronary heart disease and stroke. Aggressive lipid-lowering therapy with atorvastatin offers greater protection than moderate therapy.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Atorvastatin has been available in Turkey for 10 years, providing extensive clinical data.
- Physicians have observed atorvastatin's beneficial effects on clinical endpoints.
- This review focuses on atorvastatin's role in secondary prevention.
Purpose of the Study:
- To review clinical trial data on atorvastatin's efficacy in secondary prevention.
- To evaluate the benefits of atorvastatin in patients with coronary heart disease and stroke.
Main Methods:
- Review of key clinical trials including GREACE, ALLIANCE, TNT, MIRACL, PROVE-IT, AVERT, and SPARCL.
- Analysis of data from real-world settings and specific patient populations.
- Comparison of aggressive versus moderate lipid-lowering strategies.
Main Results:
- Atorvastatin demonstrated benefits in patients with coronary heart disease (GREACE, ALLIANCE).
- Aggressive lipid lowering with atorvastatin proved superior to moderate therapy in stable and acute coronary syndromes (TNT, PROVE-IT).
- Atorvastatin showed efficacy in preventing ischemic events (MIRACL) and secondary stroke prevention (SPARCL), and was as effective as angioplasty in stable CAD (AVERT).
Conclusions:
- Atorvastatin is effective in secondary prevention for patients with coronary heart disease.
- Aggressive lipid-lowering therapy with atorvastatin significantly improves outcomes in various cardiovascular conditions.
- Atorvastatin demonstrates broad efficacy in preventing major adverse cardiovascular events, including stroke.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:23Atherosclerosis IV: Nursing Management
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...